Plasma lipidomics-based exploration of potential biomarkers of metastasis in pediatric medulloblastoma.
10.7499/j.issn.1008-8830.2503030
- Author:
Chun-Jing YANG
1
;
Xi-Qiao XU
1
;
Li BAO
1
;
Wan-Shui WU
;
De-Chun JIANG
1
;
Zheng-Yuan SHI
1
Author Information
1. Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
- Publication Type:Journal Article
- Keywords:
Child;
Lipidomics;
Medulloblastoma;
Metastasis;
Potential biomarker;
Ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry
- MeSH:
Humans;
Medulloblastoma/diagnosis*;
Lipidomics;
Child;
Male;
Female;
Child, Preschool;
Cerebellar Neoplasms/blood*;
Biomarkers, Tumor/blood*;
Neoplasm Metastasis;
Prospective Studies;
Adolescent;
Lipids/blood*
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(11):1384-1390
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To identify potential plasma lipidomic biomarkers that distinguish non-metastatic medulloblastoma (nmMB) from metastatic medulloblastoma (mMB) in children.
METHODS:In this prospective study, 17 children with mMB and 20 matched children with nmMB were enrolled. Plasma samples were analyzed using ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. Lipid metabolites were evaluated for their associations and diagnostic performance.
RESULTS:Orthogonal partial least squares discriminant analysis based on lipid profiles clearly separated nmMB from mMB, and 14 differential lipids were identified, including DG(18:2/20:4/0:0) and SM(d18:1/20:0). Receiver operating characteristic analysis showed nine metabolites with area under the curve greater than 0.7. Differential lipids were enriched in sphingolipid, glycerophospholipid, and arachidonic acid metabolism, suggesting an association with the metastatic phenotype.
CONCLUSIONS:Plasma lipidomics provides a new approach to identify mMB, and the identified lipid metabolites may support early diagnosis and treatment, prognostic assessment, and selection of therapeutic targets for metastatic medulloblastoma.
